Market Overview

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that is used to treat hypertension (high blood pressure) and heart failure. It works by blocking the production of angiotensin II, a substance that constricts blood vessels and raises blood pressure. Lisinopril is available in generic form and under the brand names Prinivil, Zestril, and Prinzide.

The global lisinopril market is expected to reach a value of $10 billion by 2029, growing at a CAGR of 5.5% from 2023 to 2029. The market is being driven by the increasing prevalence of hypertension and heart failure, as well as the growing adoption of generic drugs.

Key Players

Actavis Elizabeth, Apotex, Aurobindo Pharma, Ivax Pharmaceuticals, Lek Pharmaceuticals, Lupin, Mylan Pharmaceuticals, Ranbaxy Pharmaceuticals, Novartis, Teva Pharmaceuticals, Vintage Pharmaceuticals, Watson Laboratories, West Ward Pharmaceutical, Wockhardt, Merck Research Laboratories, Astrazeneca, Alvogen, Hikma, Prinston, Accord Hlthcare, CASI Pharms, Invagen Pharms, and SUN Pharm

These companies are involved in the development, manufacturing, and marketing of Lisinopril, a generic drug used to treat hypertension.

Drivers:

Increasing prevalence of hypertension: Hypertension is a major risk factor for cardiovascular disease, which is the leading cause of death worldwide. The prevalence of hypertension is increasing due to factors such as obesity, unhealthy lifestyle, and aging.

Growing geriatric population: The geriatric population is more susceptible to hypertension as they are more likely to have other chronic conditions such as diabetes and kidney disease.

Rising adoption of generic drugs: Generic drugs are just as effective as brand-name drugs but are significantly cheaper. This is making them more attractive to patients and healthcare providers.

Opportunity:

Development of new formulations: New formulations of Lisinopril could be developed that are more effective, easier to take, or have fewer side effects.

Expansion into new markets: There are still many markets where Lisinopril is not yet widely available. Expanding into these markets could significantly increase sales.

Introduction of new combination therapies: Lisinopril could be combined with other drugs to create new combination therapies that are more effective than either drug alone.

To Know more - https://www.pragmamarketresearch.com/reports/120873/lisinopril-market-size

By Type

The Lisinopril market is segmented by type into 2.5mg, 5mg, 10mg, 20mg, 30mg, and 40mg. The 2.5mg and 5mg segments are expected to be the fastest growing segments over the forecast period. This is due to the increasing prevalence of hypertension in younger age groups. The 10mg, 20mg, and 30mg segments are expected to be the largest segments over the forecast period. This is due to the increasing prevalence of hypertension in older age groups. The 40mg segment is expected to be the smallest segment over the forecast period.

By Application

The Lisinopril market is segmented by application into hospital and drug store. The hospital segment is expected to be the largest segment over the forecast period due to the increasing prevalence of hypertension and the growing geriatric population. Patients with hypertension are often admitted to the hospital for treatment, and Lisinopril is a common medication used in these settings. The drug store segment is expected to grow at a faster rate over the forecast period due to the increasing availability of generic Lisinopril. Generic drugs are just as effective as brand-name drugs but are significantly cheaper. This is making them more attractive to patients and healthcare providers.

Regional Analysis

The Lisinopril market is segmented by region into North America, Europe, Asia Pacific, and Latin America. North America is expected to be the largest market over the forecast period due to the high prevalence of hypertension and the strong presence of generic drug manufacturers. Europe is also a major market for Lisinopril. The Asia Pacific market is expected to grow at the fastest rate over the forecast period due to the increasing prevalence of hypertension and the growing geriatric population. Latin America is expected to be the smallest market over the forecast period.

The global Lisinopril market is expected to grow at a CAGR of 5.5% over the forecast period of 2023-2029. The market is driven by the increasing prevalence of hypertension, the growing geriatric population, and the rising adoption of generic drugs. The key players in the market are increasingly focusing on the development of new formulations, the expansion into new markets, and the introduction of new combination therapies. These factors are expected to drive the growth of the Lisinopril market in the coming years.